Therefore, there is a strong rationale and need to develop and test novel and effective small molecule drugs for FPD/MM, with the goal of eliminating the FPD-MM clone and reverting the disease back to RUNX1-FPD state. This evidence concerns the gene RUNX1 and Miyoshi myopathy.